Den ene undersøgelse var med 670 patienter med CML i kronisk fase, den anden med 611 patienter med accelereret CML eller Ph+ ALL.
Two further studies compared the effects of Sprycel taken once or twice a day, one in 670 patients with chronic phase CML and the other in 611 patients with advanced phase CML or Ph+ ALL.